News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celgene International Sárl (CELG) Release: Data Evaluating Clinical Potential of ABRAXANE® (Nab-Paclitaxel) in Combination with Gemcitabine in Resectable Pancreatic Cancer Presented at American Society of Clinical Oncology



6/4/2012 2:55:31 PM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced results from a study of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer. These results were reported during the 48th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Ill.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES